Stock 2185 SHANGHAI BIO-HEART BIOLOGICAL TECHNOLOGY CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Shanghai Bio-heart Biological Technology Co., Ltd.

Equities

2185

CNE100004JH3

Medical Equipment, Supplies & Distribution

Delayed Hong Kong S.E.
Other stock markets
 08:39:46 03/05/2024 am IST 		5-day change 1st Jan Change
2.05 HKD -0.49% Intraday chart for Shanghai Bio-heart Biological Technology Co., Ltd. +6.77% -40.06%
25/03 Shanghai Bio-heart Biological Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Shanghai Bio-Heart Biological Technology Co., Ltd. Announces Change of Employee Representative Supervisor CI

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025
Capitalization 1 5,377 1,258 464.4 464.4 -
Enterprise Value (EV) 1 5,377 1,258 756.7 464.4 464.4
P/E ratio - -6.14 x -4.32 x -7.95 x -3.82 x
Yield - - - - -
Capitalization / Revenue - - - 22.1 x 1.58 x
EV / Revenue - - - 22.1 x 1.58 x
EV / EBITDA -13.4 x - -5.47 x -16 x -4.74 x
EV / FCF -4,38,02,412 x - - - -
FCF Yield -0% - - - -
Price to Book 5.4 x - 0.57 x 0.6 x 0.69 x
Nbr of stocks (in thousands) 2,43,937 2,43,937 2,43,417 2,43,417 -
Reference price 2 22.04 5.158 1.908 1.908 1.908
Announcement Date 18/03/22 31/03/23 25/03/24 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Net sales 1 - - - - 21 293
EBITDA 1 - -400.9 - -138.3 -29 -98
EBIT 1 - -409.7 - -159.6 -69 -142
Operating Margin - - - - -328.57% -48.46%
Earnings before Tax (EBT) 1 - - - -188.8 -69 -145
Net income 1 -340.3 - -204.2 -175.9 -59 -123
Net margin - - - - -280.95% -41.98%
EPS 2 - - -0.8400 -0.7200 -0.2400 -0.5000
Free Cash Flow - -122.7 - - - -
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 16/11/21 18/03/22 31/03/23 25/03/24 - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Net Debt - - - - - -
Net Cash position - - - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - -123 - - - -
ROE (net income / shareholders' equity) - - - -10.1% -7.52% -18.2%
ROA (Net income/ Total Assets) - -38% - -9.43% -7.1% -14.4%
Assets 1 - - - 880.2 831 854.2
Book Value Per Share 2 - 4.080 - 3.360 3.200 2.770
Cash Flow per Share 2 - - - -0.1600 -0.0100 -0.5800
Capex 1 - 34.3 - 50 70 90
Capex / Sales - - - - 333.33% 30.72%
Announcement Date 16/11/21 18/03/22 31/03/23 25/03/24 - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.06
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Medical Devices & Implants

1st Jan change Capi.
SHANGHAI BIO-HEART BIOLOGICAL TECHNOLOGY CO., LTD. Stock Shanghai Bio-heart Biological Technology Co., Ltd.
-40.06% 65.65M
STRYKER CORPORATION Stock Stryker Corporation
+9.07% 125B
SMITH & NEPHEW PLC Stock Smith & Nephew Plc
-8.61% 10.63B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD. Stock Imeik Technology Development Co.,Ltd.
+2.17% 8.92B
INSPIRE MEDICAL SYSTEMS, INC. Stock Inspire Medical Systems, Inc.
+23.48% 7.39B
GLAUKOS CORPORATION Stock Glaukos Corporation
+32.13% 4.96B
AXONICS, INC. Stock Axonics, Inc.
+7.84% 3.41B
ENOVIS CORPORATION Stock Enovis Corporation
-6.94% 3.04B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD. Stock Beijing Balance Medical Technology Co.,Ltd.
-5.07% 2.23B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD. Stock Shanghai MicroPort Endovascular MedTech Co., Ltd.
-4.22% 2.13B
Medical Devices & Implants
  1. Stock Market
  2. Equities
  3. 2185 Stock
  4. Financials Shanghai Bio-heart Biological Technology Co., Ltd.